Treatment options for its precursor, high-grade anal intraepithelial neoplasia (HGAIN), are suboptimal. In this phase I to II dose-finding study, we assessed the safety and efficacy of the human papillomavirus type 16 (HPV16) synthetic long peptide vaccine (SLP-HPV-01) in HIV+ MSM with ...
Some of these have proven to be at least partially successful, but no therapeutic vaccine has yet been licensed for the treatment of premalignant lesions or established HPV associated tumors. In addition, few strategies have been designed for the dual goal of both HPV prevention and immunotherapy ...
1997;Landis et al, 1998). Infection by human papillomavirus (HPV) is a major risk factor for the development of invasive cervical carcinoma and its precursor cervical intraepithelial neoplasia (CIN). Nearly all (99.7%) cervical cancers are positive for HPV ...
Proteome Analysis of Differential Protein Expression in Cervical Cancer Cells after Paclitaxel Treatment PURPOSE: It is well known that infection with HPV (human papillomavirus) is the main cause of cervical cancer and certain types of HPV are recognized as ca... EK Yim,JS Bae,SB Lee,... - ...
HPV-associated cervical disease is a worldwide health concern. The recently approved prophylactic vaccine against common HR types of HPV is not a treatment for cervical or any other HPV-associated cancer and is not beneficial to individuals already infected with HPV or immunocompromised patients. As...
In cases 32−41 (lower grades of dysplasia group), there was no resistance to primary treatment and only 3/10 cases recurred. Detection of HPV DNA in conjunctival in situ squamous carcinoma and lower grades of dysplasia Biopsies from the 31 cases diagnosed histologically with conjunctival in ...
HPV DNA is found in almost 80% of VIN/VaIN. Current management is inadequate, with high recurrence rates. Our objective was to review the literature regarding the role of HPV vaccine in secondary prevention and treatment of VIN/VaIN. Database searches in
These studies demonstrate that patients with positive HPV tumors have a better response to standard therapy, as well as those who over-express p16 and do not have a TP53 mutation. There is still no consensus on the best time to define the lack of clinical response to the treatment of ...
Most cervical cancers are caused by human papilloma virus (HPV), but studies on the treatment response and prognosis depending on the HPV subtype, are conflicting. This hypothesis-generating study aims to investigate the prognostic impact of GLUT1 in cervical cancer, in conjunction with HPV subtype...
HPV sublineages varied both in geographical regions and carcinogenicity. Based on over 7,000 HPV16 positive samples from 52 countries, it was found that the predominant global sublineage was A1, though some other regional predominant sublineages also existed [16]. In East Asia, the regional preva...